Basilea Pharmaceutica Ltd. Logo
 

Oncology 2009

 
 
 

Research

International Conference on Molecular Targets and Cancer Therapeutics, November 2009, Boston, United States of America

  • C-229 / BAL27862: A novel anticancer agent that dissociates microtubules and creates a distinct cellular phenotype. Bachmann F, Burger K, Pohlmann J, Kellenberger L, Lane H.  
  • C-233 / BAL27862: A unique microtubule-targeted agent with a potential for the treatment of human brain tumors. Schmitt-Hoffmann A, Klauer D, Gebhardt K, Brendle A, Fullhardt P, Hargreaves P, Bucher C, Schläfle C, Spickermann J, Defoin R, Burger K, Vuong V, Pruschy M, Bachmann F, Lane H.
 
Info